SEC Filing Summary
Important identity and period note: The provided filing is Rexahn Pharmaceuticals, Inc.’s Form 10-K for the fiscal year ended December 31, 2012, filed March 22, 2013. It is not an Opus Genetics, Inc. filing. The source provides annual results, not standalone fourth-quarter results.
Business context
Rexahn was a development-stage biopharmaceutical company focused primarily on oncology, with additional central nervous system candidates. It had no product sales and depended on financing, collaboration funding and cash reserves. Its oncology pipeline included Archexin, RX-3117 and RX-5902; Serdaxin and Zoraxel were CNS candidates whose further development depended on partners or funding.
Financial performance and position
| Metric | FY 2012 | FY 2011 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $3.39 million | $11.99 million |
| General and administrative expense | $2.71 million | $3.55 million |
| Total expenses | $6.58 million | $16.13 million |
| Net loss | $6.23 million; $0.06 per share | $11.34 million; $0.12 per share |
| Cash used in operating activities | $6.62 million | $15.53 million |
- Cash and cash equivalents were $13.49 million at year-end; marketable securities were $0.10 million and restricted cash was $1.09 million. Total cash, restricted cash and marketable securities was $14.68 million.
- Total assets were $14.92 million, total liabilities $5.39 million and stockholders’ equity $9.53 million. The company reported no debt instruments on its balance sheet.
- Financing activities provided $8.05 million in 2012, including net proceeds from equity issuance and $0.93 million of Teva research funding. Investing activities provided $2.19 million, primarily from securities sales.
- Warrant liabilities were $2.84 million, up from $0.87 million. A $0.66 million noncash gain from warrant revaluation reduced reported loss; the comparable 2011 gain was $4.78 million.
Material changes versus 2011
- Net loss narrowed by approximately $5.12 million, chiefly as R&D expense fell by $8.60 million. Management attributed most of the R&D reduction to the completion of Serdaxin’s Phase IIb trial, which had cost approximately $7.43 million in 2011, and lower RX-3117 costs.
- Operating cash use declined by approximately $8.91 million. Cash and cash equivalents increased by $3.63 million during 2012, compared with a $2.48 million decrease in 2011.
- The December 2012 public offering raised $7.26 million gross through common shares and warrants; Teva separately invested $0.75 million for shares. The company issued 12.98 million warrants during 2012, and reported 21.66 million warrants outstanding at year-end.
- R&D remained concentrated in a smaller set of programs: 2012 spending included $1.07 million for RX-3117, $0.63 million for RX-5902 and $0.17 million for Archexin.
Outlook, risks and unusual items
- Management said available cash, restricted cash and marketable securities should cover minimum planned operating needs for approximately 18 months and cash-flow requirements into 2014, assuming spending focused on selected programs. It also stated that additional financing would be needed to fund the broader development plan; financing availability and terms were uncertain.
- Planned priorities included Archexin Phase II studies and Phase I development of RX-3117 and RX-5902. These timelines and cost estimates were forward-looking and subject to clinical, regulatory and funding risks.
- Archexin’s pancreatic-cancer Phase IIa study reported median survival of 9.1 months among evaluable patients versus 5.65 months in historical gemcitabine data. This was an open-label study of 31 subjects and a historical comparison, not a randomized control comparison.
- RX-3117 completed an exploratory Phase I study demonstrating oral bioavailability, with no adverse effects reported in that study. Further development relied substantially on Teva support. RX-5902 had an IND submitted in July 2012 and was expected to enter Phase I in 2013.
- Serdaxin’s Phase IIb study did not demonstrate efficacy versus placebo on the MADRS measure; the company was not allocating resources to further MDD development. Further Zoraxel development was also contingent on obtaining a partner.
- Key risks included no product revenue, recurring losses and operating cash outflows, need for capital that could dilute shareholders, clinical and regulatory uncertainty, reliance on Teva and other third parties, and dependence on outsourced manufacturing. The company also disclosed litigation in Japan seeking correction of patent claims relating to RX-5902.
- Management reported disclosure controls and internal control over financial reporting as effective at year-end. The independent auditor gave an unmodified opinion on the financial statements.
Important facts for investors to verify
- Confirm the intended company: this filing identifies Rexahn Pharmaceuticals, Inc., not Opus Genetics, Inc.
- Review the audited statements and subsequent filings for cash runway, financing needs and any later changes to management’s stated outlook.
- Check clinical-trial progress and results for Archexin, RX-3117 and RX-5902, including whether expected trial starts occurred.
- Verify the terms, potential dilution and fair-value accounting effects of outstanding warrants and other equity-linked securities.
- Assess the status of Teva’s RX-3117 funding and license option, and the Japanese RX-5902 patent dispute.